Jump to content

FLT4

From Wikipedia, the free encyclopedia

FLT4
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesFLT4, FLT41, LMPH1A, PCL, VEGFR3, FLT-4, VEGFR-3, fms related tyrosine kinase 4, LMPHM1, fms related receptor tyrosine kinase 4, CHTD7
External IDsOMIM: 136352; MGI: 95561; HomoloGene: 7321; GeneCards: FLT4; OMA:FLT4 - orthologs
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_002020
NM_182925
NM_001354989

NM_008029

RefSeq (protein)

NP_002011
NP_891555
NP_001341918

NP_032055

Location (UCSC)Chr 5: 180.6 – 180.65 MbChr 11: 49.5 – 49.54 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Fms-related tyrosine kinase 4, also known as FLT4, is a protein which in humans is encoded by the FLT4 gene.[5][6]

This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. Mutations in this gene cause hereditary lymphedema type IA.[5]

Interactions

[edit]

FLT4 has been shown to interact with SHC1.[7][8][9]

See also

[edit]

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000037280Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000020357Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ a b "Entrez Gene: FLT4 fms-related tyrosine kinase 4".
  6. ^ Galland F, Karamysheva A, Mattei MG, Rosnet O, Marchetto S, Birnbaum D (June 1992). "Chromosomal localization of FLT4, a novel receptor-type tyrosine kinase gene". Genomics. 13 (2): 475–8. doi:10.1016/0888-7543(92)90277-Y. PMID 1319394.
  7. ^ Pajusola K, Aprelikova O, Pelicci G, Weich H, Claesson-Welsh L, Alitalo K (December 1994). "Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors". Oncogene. 9 (12): 3545–55. PMID 7970715.
  8. ^ Fournier E, Blaikie P, Rosnet O, Margolis B, Birnbaum D, Borg JP (January 1999). "Role of tyrosine residues and protein interaction domains of SHC adaptor in VEGF receptor 3 signaling". Oncogene. 18 (2): 507–14. doi:10.1038/sj.onc.1202315. PMID 9927207.
  9. ^ Fournier E, Rosnet O, Marchetto S, Turck CW, Rottapel R, Pelicci PG, Birnbaum D, Borg JP (May 1996). "Interaction with the phosphotyrosine binding domain/phosphotyrosine interacting domain of SHC is required for the transforming activity of the FLT4/VEGFR3 receptor tyrosine kinase". The Journal of Biological Chemistry. 271 (22): 12956–63. doi:10.1074/jbc.271.22.12956. PMID 8662748.

Further reading

[edit]
[edit]

This article incorporates text from the United States National Library of Medicine, which is in the public domain.